BioLife Solutions, Inc
(NASDAQ:BLFS)

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial m...

Website: http://www.biolifesolutions.com

Founded: 1987

Sector: Healthcare

Industry: Medical Instruments & Supplies

Pharmaceuticals

Share this website to your friends

• Market Cap:

• Exchange:

• Shs Outstanding:

• Employees:

• Beta:

• Return on Equity (ROE) ttm:

• Return on Assets (ROA) ttm:

• EPS ttm:

• Book value per Share:

• Cash per Share:

• Current ast per Share:

• P/E ttm:

• P/E forward:

• P/E ttm high:

• P/E ttm low:

• P/S ttm:

• P/B ttm:

• P/FCF ttm:

• PEG ratio:

• Cash Ratio ttm:

• Quick Ratio ttm:

• Current Ratio ttm:

• Gross Mgn ttm:

• EBITDA Mgn ttm:

• Operating Mgn ttm:

• Net Income Mgn ttm:

• Trailing Div yield:

• Forward Div yield:

• Payout Ratio ttm:

• Ex-Dividend date:

• Target Price High:

• Target Price Low:

• Target Price Mean:

• Number of Analysts:

• Debt Ratio ttm:

• Debt to Equity ttm:

• Total Net Debt:

At a glance:

Bull Thesis:

Bear Thesis:

Main Competitors:

Moat:

Income Statements:

Quarterly

Annual

Unit: USD	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2015-01-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31

product revenue	18,064,500	26,250,000	23,709,000	22,299,000	11,404,000	23,457,000	21,310,000	24,803,000	26,175,000	26,891,000	33,037,000	31,593,000	37,773,000	33,668,000	34,170,000	30,388,000	31,468,000	29,201,000	27,468,000	13,776,000	12,520,000	10,804,000	9,489,000	11,727,000				5,770,000				3,814,882				2,366,201				1,852,017				1,500,722
service revenue	30,500	26,000	36,000	60,000	-14,013,000	4,660,000	4,427,000	5,088,000	4,508,000	4,378,000	4,195,000	4,471,000	4,191,000	4,330,000	3,698,000	3,090,000	3,400,000	2,250,000	1,963,000	2,204,000
rental revenue	1,262,250	1,791,000	1,676,000	1,582,000	-815,000	2,454,000	2,591,000	1,836,000	2,050,000	2,059,000	2,276,000	1,639,000	2,295,000	2,749,000	2,665,000	2,742,000	2,437,000	2,349,000	1,773,000	867,000	454,000	475,000	431,000	435,000
total product, rental, and service revenue	19,357,250	28,067,000	25,421,000	23,941,000	21,419,500	30,571,000	28,328,000	31,727,000	27,634,500	33,328,000	39,508,000	37,703,000	29,375,000	40,747,000	40,533,000	36,220,000	20,462,750	33,800,000	31,204,000	16,847,000
yoy	-9.63%	-8.19%	-10.26%	-24.54%	-22.49%	-8.27%	-28.30%	-15.85%	-5.93%	-18.21%	-2.53%	4.09%	43.55%	20.55%	29.90%	114.99%
qoq	-31.03%	10.41%	6.18%	11.77%	-29.94%	7.92%	-10.71%	14.81%	-17.08%	-15.64%	4.79%	28.35%	-27.91%	0.53%	11.91%	77.00%	-39.46%	8.32%	85.22%
costs and operating expenses:
cost of product revenue	6,107,750	9,288,000	8,035,000	7,109,000	-661,000	8,765,000	8,614,000	14,384,000	18,729,000	16,665,000	21,961,000	18,397,000	25,142,000	21,876,000	21,561,000	20,384,000	26,396,000	21,672,000	15,986,000	5,622,000
cost of service revenue	6,500	7,000	9,000	10,000	-10,195,000	3,401,000	3,327,000	3,519,000	3,713,000	3,945,000	4,038,000	3,891,000	3,550,000	3,253,000	2,968,000	2,145,000	833,000	1,768,000	1,427,000	1,353,000
cost of rental revenue	707,750	851,000	944,000	1,036,000	-839,000	2,110,000	1,494,000	1,263,000	1,041,000	1,069,000	1,697,000	1,376,000	1,596,000	1,880,000	1,665,000	1,917,000	3,911,000	1,424,000	1,141,000	575,000
general and administrative	10,550,000	12,074,000	11,396,000	11,501,000	6,588,000	11,351,000	10,894,000	12,934,000	12,968,000	12,513,000	15,402,000	14,842,000	13,542,000	11,581,000	11,351,000	11,196,000	10,390,000	10,081,000	7,146,000	4,830,000	4,691,000	3,503,000	3,278,000	3,135,000		2,258,000	2,118,000	2,204,000		1,454,573	1,390,524	1,353,377	1,224,018	1,118,251	1,077,067	1,103,143	954,902	1,039,223	1,262,818	1,335,292	-3,509,810	1,263,272	1,030,701	1,220,705	1,125,396	1,011,316	969,799	863,743	-1,853,667	630,342	601,617	624,427	709,965	487,733	475,006	479,113	473,085	500,424	401,423	454,375		321,337	386,626	442,574		345,270	379,172	456,075		481,771	465,502	512,458
sales and marketing	1,993,000	2,528,000	2,732,000	2,597,000	-791,000	3,543,000	3,502,000	5,070,000	4,538,000	7,256,000	6,318,000	6,471,000	5,987,000	5,277,000	5,415,000	4,891,000	4,778,000	4,065,000	3,142,000	2,021,000	1,883,000	1,588,000	1,366,000	1,576,000		1,259,000	928,000	848,000		725,201	641,168	611,502	539,339	488,688	546,455	511,944	610,406	816,025	849,193	733,913	-1,817,194	677,033	642,490	500,255	519,467	298,263	270,616	241,400	-624,759	208,080	214,762	202,758	239,428	145,735	160,658	73,381	69,197	55,443	59,132	83,308		91,354	117,017	123,028		132,163	211,038	123,581		80,400	76,415	96,086
research and development	-67,000	2,709,000	2,719,000	2,204,000	1,085,000	2,050,000	2,382,000	3,534,000	4,399,000	5,402,000	4,840,000	4,152,000	4,164,000	3,425,000	3,428,000	3,781,000	3,571,000	3,219,000	3,045,000	1,987,000	1,855,000	1,725,000	1,477,000	1,663,000		1,309,000	739,000	372,000		312,000	324,612	346,454	294,964	293,093	318,607	286,751	428,321	496,874	599,031	504,239	-951,647	329,527	301,334	322,165	357,707	153,328	192,778	167,287	-360,916	160,528	94,908	105,968	109,801	110,689	126,627	116,521	125,368	98,903	133,390	158,793		98,350	81,502	66,932		73,267	141,946	133,624		94,133	103,377	111,302
ipr&d expense			15,521,000
intangible asset amortization	-1,846,000	699,000	708,000	702,000	3,000	910,000	910,000	914,000	915,000	1,356,000	1,450,000	1,459,000	1,461,000	2,513,000	2,863,000	2,863,000	2,862,000	2,525,000	1,882,000	933,000
total operating expenses	-16,658,000	28,156,000	42,064,000	25,159,000	-4,810,000	32,130,000	31,123,000	41,855,000	45,888,000	62,111,000	54,788,000	51,308,000	94,500,000	52,152,000	116,795,000	43,853,000	54,550,000	44,959,000	35,759,000	17,828,000	19,469,000	12,525,000	9,876,000	11,792,000		5,117,000	3,824,000	3,632,000		2,491,774	2,356,304	2,311,333	2,058,321	1,900,032	1,942,129	1,901,838	1,993,629	2,352,122	2,711,042	2,573,444	1,571,870.5	2,269,832	1,974,525	2,043,125	2,002,570	1,462,907	1,433,193	1,272,430	710,847.5	998,950	911,287	933,153	1,059,194	744,157	762,291	669,015	667,650	654,770	593,945	696,476		511,041	585,145	632,534		550,700	950,410	880,231		762,598	645,294	719,846
operating income	1,347,000	-89,000	-16,643,000	-1,218,000	1,386,000	-1,559,000	-2,795,000	-10,128,000	-13,155,000	-28,783,000	-15,280,000	-13,605,000	-50,241,000	-11,405,000	-76,262,000	-7,633,000	-17,245,000	-11,159,000	-4,555,000	-981,000	-4,743,000	-1,246,000	44,000	370,000		-597,000	919,000	491,000		1,194,998	1,284,771	139,720	-218,260	-32,345	-341,203	-464,039	-627,358	-1,137,860	-1,593,889	-1,492,432	-903,206.75	-1,296,448	-1,155,877	-1,160,502	-1,004,263	-874,513	-887,873	-369,041	-151.5	-110,093	-82,844	192,331	-307,636	-148,708	-306,630	-179,264	-210,586	-284,808	-260,012	-454,277		-286,196	-391,527	-393,814		-432,885	-892,733	-733,396		-588,498	-594,692	-560,614
yoy	-2.81%	-94.29%	495.46%	-87.97%	-110.54%	-94.58%	-81.71%	-25.56%	-73.82%	152.37%	-79.96%	78.24%	191.34%	2.20%	1574.25%	678.08%	263.59%	795.59%	-10452.27%	-365.14%		108.71%	-95.21%	-24.64%		-149.96%	-28.47%	251.42%		-3794.54%	-476.54%	-130.11%	-65.21%	-97.16%	-78.59%	-68.91%	-30.54%	-12.23%	37.89%	28.60%	-10.06%	48.25%	30.18%	214.46%	662779.87%	694.34%	971.74%	-291.88%	-99.95%	-25.97%	-72.98%	-207.29%	46.09%	-47.79%	17.93%	-60.54%		-0.48%	-33.59%	15.35%		-33.89%	-56.14%	-46.30%		-26.44%	50.12%	30.82%
qoq	-1613.48%	-99.47%	1266.42%	-187.88%	-188.90%	-44.22%	-72.40%	-23.01%	-54.30%	88.37%	12.31%	-72.92%	340.52%	-85.04%	899.11%	-55.74%	54.54%	144.98%	364.32%	-79.32%	280.66%	-2931.82%	-88.11%			-164.96%	87.17%			-6.99%	819.53%	-164.02%	574.79%	-90.52%	-26.47%	-26.03%	-44.87%	-28.61%	6.80%	65.24%	-30.33%	12.16%	-0.40%	15.56%	14.84%	-1.50%	140.59%	243491.42%	-99.86%	32.89%	-143.07%	-162.52%	106.87%	-51.50%	71.05%	-14.87%	-26.06%	9.54%	-42.76%			-26.90%	-0.58%			-51.51%	21.73%			-1.04%	6.08%
operating margin %	6.96%	-0.32%	-65.47%	-5.09%	6.47%	-5.10%	-9.87%	-31.92%	-47.60%	-86.36%	-38.68%	-36.08%	-171.03%	-27.99%	-188.15%	-21.07%	-84.28%	-33.01%	-14.60%	-5.82%	-Infinity%	-Infinity%	Infinity%	Infinity%	NaN%	-Infinity%	Infinity%	Infinity%	NaN%	Infinity%	Infinity%	Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	NaN%	-Infinity%	-Infinity%	-Infinity%	NaN%	-Infinity%	-Infinity%	-Infinity%	NaN%	-Infinity%	-Infinity%	-Infinity%
other income:
change in fair value of equity investments					-1,018,500		-4,074,000
interest income	833,000	508,000	684,000	681,000									-506,000	10,000			-101,000	-194,000	-121,000	-16,000	-5,000	16,000	18,000	29,000		110,000	137,000	171,000		79,773	32,537	8,418	123	103	76	48	26	30	445	1,919	4,612	4,729	5,482	8,237	8,650	7,658	4,517										3	20	2	21		27	76	36		168	195	681		1,052	485	4,255
other income	1,182,000	284,000	247,000	103,000	80,000	95,000	84,000	245,000	237,000	242,000	390,000	394,000	434,000	142,000	-22,000	131,000																																							5,981	88,272															10,495
total other income	2,015,000	792,000	931,000	784,000	157,000	-172,000	-4,351,000	38,000	-270,000	-234,000	5,086,000		-72,000	849,000			195,000	6,250,000	-121,000	-137,000	-649,000	113,000	-16,424,000	21,938,000													-2,937,814	-128,115	-125,823		4,612	4,729	5,482	8,237	8,650	12,058	4,517	-190,330	-149,746.5	-199,817	-199,662	-199,507	-203,952	-203,520	-192,263	-117,613	-200,584	-193,860	-176,667	-175,845		-150,536	-145,617	-137,962		-129,736	-120,195	-106,172		-74,327	-67,802	-84,913
income before income tax benefit	-3,860,750	703,000															-2,675,750	-4,909,000	-4,676,000
income tax benefit	-55,500	-82,000			131,000	28,000			43,000	-115,000	-5,000	-92,000	85,000	599,000	3,739,000	599,000	2,578,000	4,988,000	12,552,000
net income from continuing operations	-3,916,250	621,000	-15,838,000	-448,000	-3,265,250	-1,703,000	-7,146,000
discontinued operations:
loss from discontinued operations before income tax expense
income tax expense			-126,000	-14,000	-122,000			-131,000
loss from discontinued operations					10,775,000		-13,573,000
net income	11,070,000	621,000	-15,838,000	-448,000	12,459,000	-1,703,000	-20,719,000	-10,221,000	-13,382,000	-29,132,000	-10,199,000	-13,714,000	-50,228,000	-9,957,000	-72,554,000	-7,066,000	-14,472,000	79,000	7,876,000	-1,118,000	-2,128,000	-1,133,000	-16,380,000	22,308,000		9,316,000	838,000	427,000				3,482	-557,886	-318,718	-768,212	-870,290	-3,565,172	-1,265,975	-1,719,712	-1,490,513	-898,594.75	-1,291,719	-1,150,395	-1,152,265	-995,613	-862,455	-883,356	-559,371	-149,898	-309,910	-282,506	-7,176	-511,588	-352,228	-498,893	-296,877	-411,170	-478,668	-436,679	-630,122		-436,732	-537,144	-531,776		-562,621	-1,012,928	-839,568		-662,825	-662,494	-645,527
yoy	-11.15%	-136.47%	-23.56%	-95.62%	-193.10%	-94.15%	103.15%	-25.47%	-73.36%	192.58%	-85.94%	94.08%	247.07%	-12703.80%	-1021.20%	532.02%	580.08%	-106.97%	-148.08%	-105.01%		-112.16%	-2054.65%	5124.36%				12163.07%				-100.40%	-84.35%	-74.82%	-55.33%	-41.61%	296.75%	-1.99%	49.49%	29.36%	-9.74%	49.77%	30.23%	105.99%	564.19%	178.29%	212.69%	7695.03%	-70.70%	-12.01%	-43.37%	-97.58%	24.42%	-26.41%	14.25%	-52.89%		9.60%	-18.70%	18.49%		-22.38%	-46.97%	-36.66%		-15.12%	52.90%	30.06%
qoq	1682.61%	-103.92%	3435.27%	-103.60%	-831.59%	-91.78%	102.71%	-23.62%	-54.06%	185.64%	-25.63%	-72.70%	404.45%	-86.28%	926.80%	-51.17%	-18418.99%	-99.00%	-804.47%	-47.46%	87.82%	-93.08%	-173.43%			1011.69%	96.25%					-100.62%	75.04%	-58.51%	-11.73%	-75.59%	181.61%	-26.38%	15.38%	65.87%	-30.43%	12.28%	-0.16%	15.73%	15.44%	-2.37%	57.92%	273.17%	-51.63%	9.70%	3836.82%	-98.60%	45.24%	-29.40%	68.05%	-27.80%	-14.10%	9.62%	-30.70%			-18.69%	1.01%			-44.46%	20.65%			0.05%	2.63%
net income margin %	57.19%	2.21%	-62.30%	-1.87%	58.17%	-5.57%	-73.14%	-32.22%	-48.42%	-87.41%	-25.82%	-36.37%	-170.99%	-24.44%	-179.00%	-19.51%	-70.72%	0.23%	25.24%	-6.64%	-Infinity%	-Infinity%	-Infinity%	Infinity%	NaN%	Infinity%	Infinity%	Infinity%	NaN%	NaN%	NaN%	Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	NaN%	-Infinity%	-Infinity%	-Infinity%	NaN%	-Infinity%	-Infinity%	-Infinity%	NaN%	-Infinity%	-Infinity%	-Infinity%
net income per share	-0.083	0.01
continuing operations	0.08	0.01
discontinued operations
weighted-average shares used for eps calculation
basic	47,753,824	47,925,038			46,067,073									42,647,967	42,460,189			40,911,801	38,072,712,000			31,639,420	23,292,635	21,010,817
diluted	48,645,084	48,723,535			46,067,073									42,647,967	42,460,189			43,296,470	40,390,098,000			31,639,420	23,292,635	21,010,817
loss before income tax expense			-15,712,000	-434,000			-7,146,000	-10,090,000
loss from continuing operations, attributable to common shareholders:
basic and diluted			-15,838,000	-448,000	-3,265,250	-1,703,000	-7,146,000
loss from discontinued operations, attributable to common shareholders:
basic and diluted					-4,895,500		-13,573,000
loss per share from continuing operations, attributable to common shareholders:
basic and diluted			-0.33	-0.01	-0.07	-0.04	-0.16
loss per share from discontinued operations, attributable to common shareholders:
net loss attributable to common shareholders:
basic and diluted				-448				-10,221,000	-13,382,000	-29,132,000	-10,199,000	-13,714,000				-7,066,000
net income per share	-0.083	0.01
basic and diluted				-0.01				-0.22	-0.3	-0.67	-0.23	-0.32				-0.17
weighted-average shares used for eps calculation
basic and diluted				47,134,720				45,432,426	43,719,185	43,570,438	43,441,219	43,027,612	42,481,027,000			42,014,055	38,503,944,000			33,236,818	27,306,258				19,460,299
asset impairment charges										15,485,000
change in fair value of contingent consideration									-415,000	-1,580,000	-918,000	720,000	-1,406,000	2,346,000	-2,361,000	-3,335,000	1,789,000	-140,000	1,718,000	-491,000	3,103,000	-2,000	-1,463,000	-63,000
gain on settlement of global cooling escrow											5,115,000
interest expense					77,000	-267,000	-361,000	-207,000	-507,000	-476,000	-419,000	-411,000			-9,000	-163,000					-1,000	-3,000		-1,000		-1,000	-1,000	-3,000		-1,313	-1,332	-900	-1,077	-1,077														-177,308	-139,166	-185,554	-185,555	-185,555	-185,555	-185,554	-183,543	-178,777	-173,528	-171,677	-165,239	-160,542		-150,563	-145,693	-136,372		-128,292	-118,267	-106,853		-75,379	-78,782	-45,418
loss before income tax benefit					-3,242,000	-1,731,000			-13,425,000	-29,017,000	-10,194,000	-13,622,000	-50,313,000	-10,556,000	-76,293,000	-7,665,000
acquisition costs								237,000						1,000	5,000	11,000	20,000	345,000	272,000	998,000	251,000	179,000	13,000	225,000		291,000	39,000	208,000
change in fair value of investments														697,000							209,000	1,110,000
intangible asset impairment charges													40,464,000		69,900,000
other expense:
total other expense												-17,000			-31,000	-32,000
change in fair value of warrant liability																				-121,000	-866,000	-1,005,000	-16,442,000	21,914,000
gain on acquisition of sexton biotechnologies, inc.																		6,451,000
net income attributable to common shareholders:
basic													-50,228,000	-9,957,000	-72,554,000		-14,256,000	77,000	7,661,000	-1,118,000	-1,872,000	-1,133,000	-16,380,000	18,364,000
diluted													-50,228,000	-9,957,000	-72,554,000		-14,263,000	77,000	7,668,000	-1,118,000	-1,233,000	-1,133,000	-16,380,000	-174,000
net income per share	-0.083	0.01
basic													-0.528	-0.23	-1.71
diluted													-0.528	-0.23	-1.71
other expense																	-1,750	-7,000			-2,250	-5,000		-4,000
earnings per share attributable to common shareholders:
basic																	0.045			-0.03	-0.08	-0.04	-0.7	0.87
diluted																	0.043			-0.03	-0.04	-0.04	-0.7	-0.01
net income attributable to shareholders
basic													-50,228,000	-9,957,000	-72,554,000		-14,256,000	77,000	7,661,000	-1,118,000	-1,872,000	-1,133,000	-16,380,000	18,364,000
diluted													-50,228,000	-9,957,000	-72,554,000		-14,263,000	77,000	7,668,000	-1,118,000	-1,233,000	-1,133,000	-16,380,000	-174,000
earnings attributable to common shareholders
basic																			200
diluted																			190
net loss before provision for income taxes																				-1,118,000
net income attributable to stockholders
basic													-50,228,000	-9,957,000	-72,554,000		-14,256,000	77,000	7,661,000	-1,118,000	-1,872,000	-1,133,000	-16,380,000	18,364,000
diluted													-50,228,000	-9,957,000	-72,554,000		-14,263,000	77,000	7,668,000	-1,118,000	-1,233,000	-1,133,000	-16,380,000	-174,000
earnings per share attributable to common stockholders:
basic																	0.045			-0.03	-0.08	-0.04	-0.7	0.87
diluted																	0.043			-0.03	-0.04	-0.04	-0.7	-0.01
total product and rental revenue																					8,340,250	11,279,000	9,920,000	12,162,000
operating expenses
cost of product and rental revenue																					3,473,250	4,826,000	4,499,000	4,568,000
intangible assets amortization																					525,000	706,000	706,000	688,000
loss from equity method investment in savsu
gain on acquisition of savsu																										10,108,000
net income before provision for income taxes																					1,198,750	-1,133,000	-16,380,000	22,308,000						1,230,769	1,139,178
income tax
net income attributable to common stockholders:
basic													-50,228,000	-9,957,000	-72,554,000		-14,256,000	77,000	7,661,000	-1,118,000	-1,872,000	-1,133,000	-16,380,000	18,364,000
diluted													-50,228,000	-9,957,000	-72,554,000		-14,263,000	77,000	7,668,000	-1,118,000	-1,233,000	-1,133,000	-16,380,000	-174,000
earnings per share attributable to common stockholders
basic																	0.045			-0.03	-0.08	-0.04	-0.7	0.87
diluted																	0.043			-0.03	-0.04	-0.04	-0.7	-0.01
revenue																										6,604,000
cost of revenue																										2,084,000
gross profit																										4,520,000	4,743,000	4,123,000		3,686,772	3,641,075	2,451,053	1,840,061	1,867,687	1,600,926	1,437,799	1,366,271	1,214,262	1,117,153	1,081,012	-2,670,841	973,384	818,648	882,623	998,307	588,394	545,320	903,389	-2,839,022	888,857	828,443	1,125,484	751,558	595,449	455,661	489,751	457,064	369,962	333,933	242,199		224,845	193,618	238,720		117,815	57,677	146,835
yoy																										22.60%	30.26%	68.21%		97.40%	127.44%	70.47%	34.68%	53.81%	43.30%	33.00%	-151.16%	24.75%	36.46%	22.48%	-367.54%	65.43%	50.12%	-2.30%	-135.16%	-33.80%	-34.18%	-19.73%	-477.75%	49.28%	81.81%	129.81%	64.43%	60.95%	36.45%	102.21%		64.54%	72.47%	1.46%		90.85%	235.69%	62.58%
qoq																										-4.70%	15.04%			1.26%	48.55%	33.20%	-1.48%	16.66%	11.35%	5.24%	12.52%	8.69%	3.34%	-140.47%	-374.39%	18.90%	-7.25%	-11.59%	69.67%	7.90%	-39.64%	-131.82%	-419.40%	7.29%	-26.39%	49.75%	26.22%	30.68%	-6.96%	7.15%	23.54%	10.79%	37.88%			16.13%	-18.89%			104.27%	-60.72%
gross margin %	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	NaN%	NaN%	NaN%	NaN%	NaN%	Infinity%	Infinity%	Infinity%	NaN%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	-Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	-Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	Infinity%	NaN%	Infinity%	Infinity%	Infinity%	NaN%	Infinity%	Infinity%	Infinity%	NaN%	NaN%	NaN%	NaN%
other income (expenses)
loss on disposal of assets																										-13,000
loss from equity-method investment in savsu																										-291,000	-217,000	-232,000		-42,689	-176,798	-143,756	-297,672	-217,735	-260,105
total other income (expenses)																										9,913,000	-81,000	-64,000		35,771	-145,593	-136,238	-279,908.25	-286,373	-427,009	-406,251
income before provision for income taxes																										9,316,000	838,000
income taxes
less: preferred stock dividends																														-79,675	-93,258	-106,250	-106,250	-106,250
net income attributable to common stockholders																										9,316,000	838,000	427,000		1,151,094	1,045,920
basic net income per common share																										470	40	20		0.07	0.07
diluted net income per common share																										370	30	20		0.05	0.05
basic shares used to compute earnings per share																										19,735,364	18,819,459				15,180,169
diluted shares used to compute earnings per share																										25,343,112	24,539,299				20,374,358
product sales																											6,701,000			5,293,075	5,177,854		3,134,444	2,963,411	2,557,765		2,249,790	2,135,197	1,989,988		1,157,351.75	1,631,926	1,496,759		1,670,396	1,243,372	1,211,900	2,065,030	1,512,838.5	2,170,491	2,330,018	1,550,845	2,043,220	1,676,480	1,092,409	830,880	804,564	710,518	617,848	605,799		519,892	462,771	507,909		441,526	271,528	367,945		296,620	266,713	306,384
cost of product sales																											1,958,000	1,647,000	6,157,746	1,606,303	1,536,779	1,363,829	1,294,383	1,095,724	956,839	928,402	883,519	920,935	872,835	771,005	488,688	658,542	678,111	618,099	672,089	654,978	666,580	1,161,641	954,434.25	1,281,634	1,501,575	1,034,528	1,296,662	1,086,031	641,748	346,129	352,500	345,556	288,915	368,600		300,047	274,153	274,189		329,545	218,851	230,277		133,770	227,361	158,402
weighted-average shares outstanding used to compute basic earnings per share																												18,648,397	16,256,465	17,273,412
weighted-average shares outstanding used to compute diluted earnings per share																												24,358,475	21,627,278	23,656,633
write-off of deferred financing costs																																	-16,916	-67,664			-21,684		-86,736
amortization of debt discount																																			-62,398	-93,598	-93,597	-93,598	-31,199
net income after provision for income taxes																														1,230,769	1,139,178
net loss attributable to common stockholders																																-102,768	-664,136	-424,968
basic and diluted net loss per common share																																-0.01																-0.1																		-0.01	-0.01	-0.01
basic and diluted weighted-average common shares used to calculate net loss per common share																																14,098,610	13,263,881	13,238,248	13,100,820			12,699,419				12,157,575	12,144,776	12,100,588	10,447,030			5,568,802								69,679,854										69,639,854	69,639,854	69,639,854
loss on disposal of property and equipment																																						-1,213																		-63	283	-1,896						-1,626		-1,612	-2,123
net loss attributable to non-controlling interest																																					231,072	296,974			124,957.5	223,031	156,016	120,783
net loss attributable to biolife solutions, inc.																																	-557,886	-318,718	-768,212		-887,978	-969,001			-773,637.25	-1,068,688	-994,379	-1,031,482
basic and diluted net loss per common share attributable to biolife solutions, inc.																																	-0.05	-0.03	-0.06		-0.07	-0.08			-0.065	-0.09	-0.08	-0.09
interest expense, related party																																			-104,582	-83,333	-58,333	-33,334	-8,333
income from equity-method investment in savsu																																				-229,368
net income attributable to non-controlling interest																																							363,629	263,685
net income attributable to biolife solutions, inc.																																				-870,290			-1,356,083	-1,226,828
basic and diluted net income per common share attributable to biolife solutions, inc.																																				-0.07			-0.11	-0.1
basic and diluted weighted-average common shares used to calculate net income per common share																																				12,964,639	12,642,996		12,568,041	12,457,858						12,042,739	12,010,361			70,106,312	70,035,710	69,873,598	69,679,854	69,679,854	69,679,854		69,679,854	69,679,854	69,679,854	69,679,854		69,679,854	69,679,854	69,679,854					69,631,566	69,639,854	69,639,854	69,606,520
gain on disposal of property and equipment																																																						431
amortization of deferred financing costs																																																-13,022	-10,580.5	-14,263	-14,107	-13,952	-18,397	-18,397	-14,701	-27,045	-27,342	-20,307	-11,430	-15,324												-43,750
licensing revenue																																																	-608,558			609,167	5,000	5,000	5,000	5,000	5,000	5,000	5,000	5,000		5,000	5,000	5,000		5,834	5,000	9,167		11,250	11,250	11,250
total revenue																																													1,670,396	1,243,372	1,211,900	2,065,030	-6,651,572	2,170,491	2,330,018	2,160,012	2,048,220	1,681,480	1,097,409	835,880	809,564	715,518	622,848	610,799		524,892	467,771	512,909		447,360	276,528	377,112		307,870	277,963	317,634
gain on sale of property and equipment																																													1,100	4,400
basic and diluted net income per common share																																													-0.058	-0.07	-0.07		-0.003					-0.01	-0.01		-0.01	-0.01	-0.01	-0.01		-0.01	-0.01	-0.01						-0.01	-0.01	-0.01
loss on sale of assets
manufacturing start-up costs																																																																			218,254	166,951		106,294
gross margin																																																																						174,100	50,602	159,232

Balance Sheets:

Quarterly

Annual

Unit: USD	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2015-01-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-09-30	2008-06-30	2008-03-31

assets
current assets:
cash and cash equivalents	33,038,000	29,481,000	31,902,000	66,945,000	95,386,000	23,977,000	22,014,000	29,694,000	35,407,000	19,235,000	21,400,000	19,105,000	19,442,000	27,036,000	24,001,000	59,463,000	69,860,000	75,098,000	76,246,000	89,012,000	90,403,000	93,984,000	29,879,000	6,400,000	6,448,000	21,205,000	19,617,000	31,824,000	30,657,000	32,380,674	14,166,604	7,032,513	6,663,318	2,830,541	2,314,633	2,289,926	1,405,826	1,368,583	1,318,469	1,662,431	2,173,258	2,351,540	3,896,405	2,971,840	2,538,758	2,538,758	3,275,057	5,902,228	12,839,600	156,273	79,287	76,205	61,523	196,478	7,529	155,354	70,524	16,864	20,117	36,145	35,097	3,211	298	67,881	2,292	139,151	95,814	86,403	428,196	85,070	87,715	136,182
available-for-sale securities, current portion	55,889,000	49,473,000	49,864,000	21,635,000	9,198,000	10,211,000	12,120,000	15,579,000	16,288,000	21,794,000	24,858,000	35,780,000	43,260,000	34,583,000	22,546,000
accounts receivable, trade, net of allowance for credit losses of 22 and 152 as of december 31, 2025 and december 31, 2024, respectively	7,953,000
inventories	30,155,000	27,825,000	27,690,000	27,566,000	29,013,000	32,179,000	32,496,000	43,414,000	43,456,000	43,354,000	39,177,000	41,329,000	34,904,000	33,747,000	33,335,000	30,200,000	28,345,000	29,696,000	25,866,000	11,666,000	11,602,000	11,037,000	10,890,000	10,829,000	10,972,000	5,694,000	5,306,000	4,060,000	3,509,000	2,910,927	2,121,881	1,836,666	1,846,746	1,861,058	1,769,070	1,812,172	1,757,784	1,903,759	1,910,729	2,018,255	1,834,635	1,783,383	1,321,257	1,242,787	965,224	965,224	717,624	678,156	297,105	420,924	409,195	593,138	676,438	656,397	849,211	916,810	763,967	505,956	475,126	509,572	447,306	410,486	499,450	532,431	436,529	358,219	237,651	379,230	453,011	587,726	121,655	97,047
prepaid expenses and other current assets	9,526,000	8,945,000	5,916,000	5,816,000	5,996,000	4,914,000	3,475,000	4,408,000	6,765,000	7,854,000	7,985,000	6,201,000	6,879,000	8,041,000	6,890,000	4,757,000	4,427,000	5,426,000	4,156,000	5,143,000	4,648,000	1,668,000	1,134,000	1,016,000	1,348,000	855,000	384,000	346,000	353,000	298,005	352,507	330,904	399,502	320,318	422,408	419,124	270,814	381,883	402,342	435,592	384,414	453,789	313,412	289,018	360,521	360,521	320,761	312,148	202,784	291,745	140,077	165,292	201,801	174,731	122,914	76,657	68,299	90,444	90,903	66,530	77,782	62,377	69,837	73,267	85,747	79,635	138,814	44,655	123,816
current assets, discontinued operations
total current assets	136,561,000	126,566,000	125,432,000	131,129,000	148,761,000	89,383,000	88,200,000	111,700,000	120,604,000	116,824,000	120,311,000	132,789,000	138,452,000	135,874,000	118,057,000	118,701,000	125,859,000	130,505,000	127,414,000	116,543,000	114,712,000	127,784,000	46,254,000	26,450,000	24,113,000	32,067,000	29,139,000	39,157,000	37,564,000	38,288,948	18,807,407	10,243,898	9,930,881	6,367,032	5,679,147	5,581,995	4,628,070	4,965,231	4,915,555	5,306,538	6,972,937	8,283,091	9,296,889	10,961,142	12,165,762	12,165,762	12,832,803	13,471,381	14,665,053	1,878,258	1,655,417	1,815,609	1,915,919	1,627,759	1,777,597	1,508,011	1,374,606	1,160,407	1,044,823	1,007,571	916,886	814,973	886,643	958,820	883,340	892,370	841,608	709,480	1,329,890	1,168,198	744,908	743,048
property and equipment	14,713,000	11,101,000	7,665,000	6,605,000	6,084,000	17,709,000	17,256,000	21,042,000	21,077,000	20,998,000	25,565,000	26,100,000	23,638,000	21,737,000	19,117,000	18,259,000	17,657,000	17,462,000	16,450,000	11,231,000	10,120,000	5,300,000	5,347,000	5,407,000	5,572,000
operating lease right-of-use assets	7,466,000	7,633,000	9,534,000	10,128,000	10,674,000	14,402,000	10,400,000	10,779,000	11,446,000	12,651,000	14,935,000	15,592,000	15,292,000	15,832,000	17,306,000	18,161,000	18,705,000	17,157,000	17,400,000	10,524,000	9,675,000	585,000	740,000	892,000	1,040,000	1,177,000	1,079,000	1,196,000
other assets	3,050,000	2,419,000
available-for-sale securities, long term	31,250,000				4,628,000				548,000				1,332,000
equity investments				995,000	995,000	995,000	995,000	5,069,000	5,069,000	5,069,000	5,069,000	5,069,000	5,069,000	5,069,000	4,372,000
intangible assets	4,257,000	7,450,000	8,149,000	8,857,000	9,559,000	18,415,000	19,325,000	20,235,000	21,149,000	22,064,000	29,177,000	30,629,000	32,088,000	74,013,000	76,524,000	149,286,000	152,149,000	155,011,000	148,714,000	30,116,000	31,049,000	19,882,000	20,588,000	21,294,000	21,982,000	16,485,000	4,446,000
goodwill	208,587,000	212,304,000	212,304,000	212,304,000	212,304,000	224,741,000	224,741,000	224,741,000	224,741,000	224,741,000	224,741,000	224,741,000	224,741,000	224,741,000	224,741,000	224,741,000	224,741,000	223,936,000	195,664,000	58,449,000	58,449,000	33,506,000	33,506,000	33,506,000	33,637,000	28,351,000	9,524,000
long-term assets, discontinued operations
total assets	405,884,000	392,081,000	387,240,000	395,141,000	399,487,000	381,652,000	374,976,000	401,602,000	412,714,000	411,152,000	433,177,000	446,470,000	450,229,000	487,679,000	470,379,000	544,012,000	554,057,000	559,391,000	520,969,000	240,024,000	234,829,000	195,887,000	113,970,000	94,987,000	92,816,000	84,228,000	51,742,000	48,073,000	45,467,000	46,448,976	21,787,020	12,293,079	12,143,203	8,881,486	8,481,722	8,598,774	7,926,614	10,766,378	10,550,454	10,775,853	12,369,622	13,225,577	13,870,187	15,160,420	16,072,918	16,072,918	14,254,063	14,806,565	15,981,534	3,353,342	3,207,024	3,437,081	3,419,277	3,169,829	3,417,833	3,068,907	1,869,170	1,662,017	1,564,376	1,471,981	1,386,251	1,309,059	1,293,655	1,384,760	1,328,018	1,333,958	1,310,008	1,203,450	1,745,300	1,302,592	850,725	854,527
liabilities and shareholders’ equity
current liabilities:
accounts payable	1,486,000	2,890,000	3,209,000	3,297,000	3,573,000	3,838,000	4,213,000	4,984,000	6,940,000	11,980,000	10,686,000	15,525,000	15,367,000	13,140,000	11,537,000	11,711,000	14,945,000	14,296,000	9,847,000	4,276,000	3,672,000	2,355,000	3,077,000	3,522,000	3,119,000	1,570,000	876,000	1,264,000	720,000	1,089,553	842,941	586,334	690,702	420,387	531,919	638,014	710,719	1,085,723	864,452	772,870	1,029,373	978,279	640,271	900,348	474,662	474,662	168,838	170,106	707,983	867,070	840,498	1,041,717	1,053,911	862,492	1,064,283	531,616	534,001	403,103	310,442	347,063	276,515	117,068	228,898	343,280	268,227	192,834	211,825	400,277	586,150	654,625	362,567	284,014
accrued expenses and other current liabilities	11,974,000	10,905,000	9,311,000	8,213,000	12,451,000	8,449,000	8,128,000	8,863,000	11,932,000	8,568,000	10,114,000	10,701,000	9,782,000	7,778,000	7,187,000	6,966,000	7,142,000	12,057,000	9,911,000	8,146,000	5,369,000	3,364,000	2,606,000	3,080,000	3,369,000	642,000	204,000	142,000	91,000	162,981	172,879	202,779	200,548	170,419	63,619	69,327	116,399	50,614	80,037	113,340	146,438	150,980	62,741	160,898	121,869	121,869	90,475	10,440	30,044	146,626	52,532	51,820	19,981	8,495	149,609	126,224	58,207	69,582			81,420	108,015
sales taxes payable	2,279,000	3,681,000	3,575,000	3,929,000	4,256,000	4,351,000	4,860,000	5,395,000	5,442,000	5,469,000	4,989,000	4,585,000	4,151,000
lease liabilities, operating, current portion	2,243,000	2,178,000	2,166,000	1,835,000	1,511,000	2,788,000	2,504,000	2,645,000	2,797,000	2,906,000	2,915,000	2,906,000	2,860,000	2,769,000	2,733,000	2,795,000	2,758,000	2,648,000	2,223,000	1,455,000	1,107,000	729,000	844,000	826,000	804,000
debt, current portion	4,997,000	7,492,000	10,051,000	10,449,000	10,943,000	12,231,000	10,614,000	8,619,000	6,833,000	5,034,000	1,935,000	1,250,000	1,814,000	2,067,000	1,363,000	557,000	862,000	1,771,000	2,924,000
current liabilities, discontinued operations
total current liabilities	22,979,000	27,146,000	28,312,000	27,723,000	32,734,000	32,166,000	30,819,000	38,658,000	42,178,000	42,622,000	39,587,000	47,319,000	44,582,000	36,948,000	33,298,000	35,040,000	40,381,000	35,793,000	31,275,000	16,381,000	15,573,000	8,362,000	7,490,000	25,460,000	7,669,000	4,944,000	3,093,000	2,701,000	1,939,000	2,095,365	1,663,728	1,311,577	1,512,898	1,089,343	1,045,091	1,085,580	1,133,163	3,464,488	2,263,541	1,479,984	1,725,793	1,631,901	1,160,156	1,464,385	1,261,776	1,261,776	833,014	613,004	1,063,655	1,628,140	1,228,905	1,423,192	1,473,479	1,365,338	1,468,094	1,021,142	687,813	579,248	516,148	502,774	463,845	340,702	10,377,601	10,062,273	9,506,001	356,673	8,654,441	8,098,243	7,658,186	1,030,087	507,517	441,305
lease liabilities, operating, long-term	10,657,000	11,007,000	11,598,000	12,165,000	12,723,000	15,189,000	11,075,000	12,579,000	13,205,000	13,677,000	14,388,000	15,114,000	14,962,000	14,474,000	15,205,000	15,917,000	16,466,000	15,047,000	15,474,000	9,299,000	8,757,000	26,000	116,000	332,000	550,000
debt, long-term				2,499,000	4,997,000	7,823,000	10,451,000	15,681,000	18,311,000	20,937,000	23,572,000	23,692,000	23,793,000	24,207,000	6,188,000	6,313,000	6,353,000	6,122,000	5,019,000
deferred tax liabilities	189,000	189,000	175,000	130,000	124,000	100,000	193,000	193,000	188,000	286,000	263,000	263,000	250,000	389,000	1,149,000	4,888,000	5,487,000	7,269,000	10,973,000
other long-term liabilities	171,000												10,000	55,000	101,000	73,000	42,000	48,000	56,000	980,000	726,000	262,000	133,000		4,000	3,000	7,000	13,000	31,000	37,855	45,364	52,520	45,512	51,235	56,141
long-term liabilities, discontinued operations
total liabilities	33,996,000	38,342,000	40,085,000	42,517,000	50,578,000	56,191,000	53,534,000	68,197,000	75,051,000	79,135,000	81,049,000	88,363,000	86,041,000	79,430,000	58,066,000	65,492,000	73,920,000	70,132,000	68,688,000	31,247,000	29,583,000	9,036,000	8,127,000	27,278,000	49,362,000	7,266,000	5,476,000	3,707,000	2,319,000	2,519,333	2,131,920	1,821,615	2,050,617	1,666,943	1,660,764	5,795,088	4,760,474	4,178,239	3,004,429	2,246,028	2,510,251	2,441,176	1,993,132	2,312,426	2,136,601	2,136,601	1,586,856	1,408,149	1,904,385	16,624,863	16,066,394	16,099,775	15,819,636	15,655,852	15,453,615	14,809,595	13,299,845	12,842,503	12,385,875	11,955,824	11,486,656	10,857,971	10,511,768	10,201,440	9,650,168	9,160,940	8,808,608	8,165,743	7,728,186	5,686,992	4,589,043	3,944,049
commitments and contingencies
shareholders’ equity:
preferred stock, 0.001 par value...																														3	3	4	4	4	4
accounts receivable, trade, net of allowance for credit losses of 105 and 153 as of september 30, 2025 and december 31, 2024, respectively		10,842,000
assets held for rent		5,164,000	5,307,000	5,690,000	6,103,000	10,822,000	11,094,000	6,904,000	7,713,000	7,209,000	9,417,000	9,005,000	9,064,000	9,357,000	9,083,000	9,823,000	9,809,000	10,086,000	8,492,000	6,503,000	4,705,000	5,131,000	4,958,000	4,875,000	3,922,000	2,976,000
available-for-sale securities, long-term		19,444,000	18,471,000	19,055,000		4,884,000	2,688,000	822,000		1,156,000	1,839,000	2,019,000		490,000	489,000
common stock, 0.001 par value...		48,000	48,000	48,000				46,000	45,000	44,000	43,000	43,000	43,000	43,000	43,000	42,000	42,000	41,000	41,000	34,000	33,000	32,000	26,000	21,000	21,000	20,000	19,000	19,000	19,000	18,237	16,107	14,145	14,021	13,333	13,210	13,017	12,864	12,769	12,607	12,508	12,447	12,172	12,154	12,107	12,084	12,084	12,053	12,027	11,941	5,030	70,415	70,036	70,036	69,680	69,680	69,680	69,680	69,680			69,680	69,680				69,680	69,640	69,640	69,640		69,640
additional paid-in capital		704,327,000	698,423,000	688,092,000				659,063,000	651,305,000	632,593,000	623,412,000	619,227,000	611,739,000	604,060,000	597,810,000	591,002,000	585,397,000	579,929,000	542,864,000	307,246,000	302,598,000	282,076,000	199,941,000	145,432,000	143,485,000	137,392,000	116,013,000	114,951,000	114,160,000	115,775,040	92,653,721	84,517,966	84,036,444	80,494,953	79,676,523	74,891,236	74,355,645	74,027,593	73,719,666	72,983,853	72,823,398	72,347,856	72,149,598	71,969,748	71,911,328	71,911,328	71,862,179	71,727,860	71,519,816	43,618,686	43,480,884	43,368,029	43,347,858	43,255,374	43,194,027	43,136,893	42,948,013	42,901,325	42,849,142	42,708,130	42,654,888	42,576,260	42,436,420	42,393,781	42,351,167	42,314,560	42,287,747	42,261,432	42,229,912	42,184,559	42,167,816	42,154,117
accumulated other comprehensive income, net of tax		130,000
accumulated deficit		-350,766,000	-351,387,000	-335,549,000				-325,138,000	-313,342,000	-299,960,000	-270,828,000	-260,629,000	-246,915,000	-194,597,000	-184,640,000	-112,086,000	-105,020,000	-90,548,000	-90,627,000	-98,503,000	-97,385,000	-95,257,000	-94,124,000	-77,744,000	-100,052,000	-60,450,000	-69,766,000	-70,604,000	-71,031,000	-71,863,637	-73,014,731	-74,060,651	-73,957,883	-73,293,747	-72,868,779	-72,100,567	-71,202,369	-67,878,835	-66,909,834	-65,553,751	-64,326,923	-63,207,536	-62,138,848	-61,144,469	-60,112,987	-60,112,987	-59,200,419	-58,337,964	-57,454,608	-56,895,237		-56,100,759	-55,818,253	-55,811,077	-55,299,489	-54,947,261	-54,448,368	-54,151,491	-53,740,321	-53,261,653	-52,824,973	-52,194,852	-51,724,213	-51,280,141	-50,742,997	-50,211,222	-49,855,987	-49,293,365	-48,282,438	-46,638,599	-45,975,774	-45,313,279
total shareholders’ equity		353,739,000	347,155,000	352,624,000				333,405,000	337,663,000	332,017,000	352,128,000	358,107,000	364,188,000	408,249,000	412,313,000	478,520,000	480,137,000	489,259,000	452,281,000	208,777,000	205,246,000	186,851,000	105,843,000	67,709,000	43,454,000	76,962,000	46,266,000	44,366,000	43,148,000	43,929,643	19,655,100	10,471,464		7,214,543	6,820,958	2,803,686			7,546,025	8,529,825
total liabilities and shareholders’ equity		392,081,000	387,240,000	395,141,000				401,602,000	412,714,000	411,152,000	433,177,000	446,470,000	450,229,000	487,679,000	470,379,000	544,012,000	554,057,000	559,391,000	520,969,000	240,024,000	234,829,000	195,887,000	113,970,000	94,987,000	92,816,000	84,228,000	51,742,000	48,073,000	45,467,000	46,448,976	21,787,020	12,293,079	12,143,203	8,881,486	8,481,722	8,598,774			10,550,454	10,775,853
accounts receivable, trade, net of allowance for credit losses of 134 and 153 as of june 30, 2025 and december 31, 2024, respectively			10,060,000
long-term deposits and other assets			378,000	378,000	379,000	271,000	241,000	245,000	273,000	316,000	316,000	284,000	281,000	256,000	323,000	265,000	325,000	386,000	452,000	356,000	230,000	35,000	36,000	36,000	50,000
accumulated other comprehensive loss, net of taxes			71,000	33,000				-566,000	-345,000	-660,000	-499,000	-534,000	-679,000	-1,257,000	-900,000	-438,000	-282,000
accounts receivable, trade, net of allowance for credit losses of 117 and 153 as of march 31, 2025 and december 31, 2024, respectively				9,167,000
accounts receivable, trade, net of allowance for credit losses of 153 and 1,603 as of december 31, 2024 and december 31, 2023, respectively					9,168,000
restricted cash						184,000	31,000	31,000	31,000	31,000	31,000	31,000	31,000	31,000	28,000	10,000	10,000	53,000	53,000	53,000	53,000
accounts receivable, trade, net of allowance for credit losses of 955 and 1,707 as of september 30, 2024 and december 31, 2023, respectively						17,918,000
financing lease right-of-use assets						30,000	36,000	65,000	94,000	124,000	1,807,000	242,000	272,000	310,000	367,000	404,000	440,000	476,000	511,000	430,000	17,000
warranty liability						186,000	183,000	7,800,000	7,858,000	8,215,000	8,436,000	8,895,000	8,312,000	8,367,000	8,722,000	9,176,000	9,398,000
lease liabilities, financing, current portion						323,000	317,000	352,000	376,000	398,000	426,000	161,000	158,000	156,000	153,000	151,000	149,000	146,000	144,000	114,000	8,000
lease liabilities, financing, long-term						913,000	996,000	1,086,000	1,169,000	1,250,000	1,330,000	95,000	126,000	166,000	213,000	253,000	291,000	329,000	367,000	316,000	12,000
accounts receivable, trade, net of allowance for credit losses of 1,061 and 1,710 as of june 30, 2024 and december 31, 2023, respectively							18,064,000
accounts receivable, trade, net of allowance for credit losses of 1,745 and 1,710 as of march 31, 2024 and december 31, 2023, respectively								18,574,000
accounts receivable, trade, net of allowance for credit losses of 1,710 and 739 as of december 31, 2023 and december 31, 2022, respectively									18,657,000
contingent consideration, current portion										52,000	86,000	3,296,000	2,138,000	2,671,000	1,603,000	3,684,000	5,127,000	2,714,000	2,854,000	2,390,000	2,637,000			365,000	377,000
contingent consideration, long-term										363,000	1,909,000	1,880,000	2,318,000	3,191,000	1,912,000	3,008,000	4,900,000	5,524,000	5,524,000	4,271,000	4,515,000	386,000	388,000	1,486,000
accounts receivable, trade, net of allowance for credit losses of 1,244 and 739 as of september 30, 2023 and december 31, 2022, respectively										24,556,000
accounts receivable, trade, net of allowance for doubtful accounts of 1,265 and 739 as of june 30, 2023 and december 31, 2022, respectively											26,860,000
accounts receivable, trade, net of allowance for doubtful accounts of 956 and 739 as of march 31, 2023 and december 31, 2022, respectively												30,343,000
accounts receivable, trade, net of allowance for doubtful accounts of 739 and 275 as of december 31, 2022 and december 31, 2021, respectively													33,936,000
accounts receivable, trade, net of allowance for doubtful accounts of 496 and 275 as of september 30, 2022 and december 31, 2021, respectively														32,436,000
accounts receivable, trade, net of allowance for doubtful accounts of 458 and 275 as of june 30, 2022 and december 31, 2021, respectively															31,257,000
accounts receivable, trade, net of allowance for doubtful accounts of 275 and 275 as of march 31, 2022 and december 31, 2021, respectively																24,271,000
investments																4,372,000	4,372,000	4,372,000	5,872,000	5,872,000	5,872,000	3,610,000	2,500,000	2,500,000	2,500,000	1,000,000
accounts receivable, trade, net of allowance for doubtful accounts of 275 and 85 as of december 31, 2021 and december 31, 2020, respectively																	23,217,000
warrant liability																								17,667,000	39,602,000
accounts receivable, trade, net of allowance for doubtful accounts of 287 and 85 as of september 30, 2021 and december 31, 2020, respectively																		20,232,000
line of credit																		2,161,000	3,372,000
warrant liability, current portion																					2,780,000	1,914,000	963,000
accumulated other comprehensive loss																		-163,000																							-451	-601	-1,390	-949	-6,448	-6,448
current assets
accounts receivable, trade, net of allowance for doubtful accounts of 107 and 85 as of june 30, 2021 and december 31, 2020, respectively																			21,093,000
current liabilities
shareholders’ equity
accumulated other comprehensive income																			3,000																													-3,507
accounts receivable, trade, net of allowance for doubtful accounts of 80 and 85 at march 31, 2021 and december 31, 2020, respectively																				10,669,000
accounts receivable, trade, net of allowance for doubtful accounts of 85 and 68 at december 31, 2020 and 2019, respectively																					8,006,000
warrant liability, long-term
restricted cash in escrow																						15,000,000
accounts receivable, trade																						6,095,000	4,351,000	8,205,000
accrued interest receivable																						54,000	41,000	27,000
accounts receivable, trade, net of allowance for doubtful accounts of 68 and 0 at december 31, 2019 and 2018, respectively																									5,345,000
equity method investment in savsu
contingent consideration, long term																									1,537,000
accounts receivable, trade, net of allowance for doubtful accounts of 68 and 0 at september 30, 2019 and december 31, 2018, respectively																										4,313,000
leasehold improvements																										1,599,000	1,284,000	1,284,000	1,284,000	1,284,491	1,284,491	1,284,491	1,284,491	1,284,491	1,284,491	1,284,491	1,284,491	1,284,491	1,284,491	1,284,491	1,284,491	1,284,491	1,284,491	1,284,491	1,284,491	1,284,491	1,121,362	1,121,362	1,121,362	1,121,362	1,121,362	1,121,362	941,925	919,035	943,878	864,361	3,936									202,270	202,270	202,270
furniture and computer equipment																										588,000	577,000	704,000	706,000	705,948	693,399	692,270	682,466	681,096	681,096	667,213	650,912	677,734	652,941	584,603	557,666	535,768	514,056	500,313	476,788	476,788	325,691	334,159	309,626	300,581	300,143	296,832	294,930	288,725	286,280	245,503	187,147	177,013	174,166	174,166	172,906	170,256	166,243	166,243	163,123	164,964	164,964	164,748	120,693	105,418	96,462	85,387
manufacturing and other equipment																										2,247,000	1,733,000	1,803,000	1,657,000	1,510,729	1,229,318	1,194,659	1,148,006	1,075,049	1,061,791	943,071	922,220	922,647	1,029,600	1,025,521	1,025,521	1,017,262	1,007,127	989,989	972,386	972,386	944,089	828,379	773,990	764,258	763,135	757,060	746,613	741,771	739,516	708,382	655,098	623,782	592,941	582,136	553,600	542,775	534,828	531,874	530,649	319,224	319,224	319,224	256,069	210,558	183,887	177,827
subtotal																										4,434,000	3,594,000	3,791,000	3,647,000	3,501,168	3,207,208	3,171,420	3,114,963	3,040,636	3,027,378	2,894,775	2,857,623	2,884,872	2,967,032	2,894,615	2,867,678	2,837,521	2,805,674	2,774,793	2,733,665	2,733,665	2,391,142	2,283,900	2,204,978	2,186,201	2,184,640	2,175,254	1,983,468	1,949,531	1,969,674	1,818,246	846,181	800,795	767,107	756,302	726,506	713,031	701,071	698,117	693,772	686,458	686,458	686,242	579,032	315,976	280,349	263,214
less: accumulated depreciation																										-2,298,000	-2,276,000	-2,424,000	-2,328,000	-2,234,286	-2,163,430	-2,084,769	-2,008,927	-1,930,140	-1,846,496	-1,759,794	-1,670,245	-1,585,914	-1,605,173	-1,513,071	-1,421,279	-1,333,608	-1,246,787	-1,161,706	-1,078,060	-1,078,060	-1,006,048	-984,882	-924,663	-862,157		-733,347	-673,782	-615,085	-555,459	-501,767	-472,780	-447,393			-375,203	-352,331
net property and equipment																										2,136,000	1,318,000	1,367,000	1,319,000	1,266,882	1,043,778	1,086,651	1,106,036	1,110,496	1,180,882	1,134,981	1,187,378	1,298,958	1,361,859	1,381,544	1,446,399	1,503,913	1,558,887	1,613,087	1,655,605	1,655,605	1,385,094	1,299,018	1,280,315	1,324,044	1,386,305	1,441,907	1,309,686	1,334,446	1,414,215	1,316,479	373,401	353,402	344,003	357,778	351,303	360,700	370,846	389,774	408,512	405,422	432,234	457,804	379,244	134,394	105,817	111,479
long-term deposits																										36,000	136,000	36,000	36,000			36,166	36,166
accrued compensation																										1,576,000	963,000	630,000	998,000	712,615	517,692	392,248	491,432	368,321	286,063	248,023	175,829	408,004	523,694	463,558	419,766	372,426	326,928	272,923	535,029	535,029	373,417	314,957	208,127	503,194	224,625	218,405	288,337	363,101	136,322	97,351	75,605	86,563	85,261	87,689	85,910	95,619	102,108	103,987	105,671	92,588
lease liability - operating, current portion																										771,000	665,000	651,000
lease liability – financing, current portion																										14,000	14,000	14,000
deferred rent, current portion																													130,000			130,216	130,216			130,216	130,216				130,216
contingent consideration - current																										371,000	371,000
deferred rent, long-term																													349,000	386,113	422,828	457,518	492,207	526,365	559,532
long-term lease liability - operating																										753,000	806,000	980,000
long-term lease liability - financing																										6,000	10,000	13,000
contingent consideration – long-term																										1,560,000	1,560,000
accounts receivable, trade, net of allowance for doubtful accounts of 26 and 0 at june 30, 2019 and december 31, 2018, respectively																											3,832,000
investment in savsu																											6,100,000	6,317,000	6,548,000	6,856,980	1,899,669	926,364	1,070,120	1,367,792	1,585,527	1,845,632	2,075,000
accounts receivable, trade, net of allowance for doubtful accounts of 0 at march 31, 2019 and december 31, 2018																												2,927,000
accounts receivable, trade, net of allowance for doubtful accounts of 0 and 6 at december 31, 2018 and 2017, respectively																													3,045,000
accounts receivable, trade, net of allowance for doubtful accounts of 0 and 5,575 at september 30, 2018 and december 31, 2017, respectively																														2,699,342
long term deposits																														36,166	36,166			36,166	36,166	36,166	36,166	36,166	36,166	36,166	36,166	36,166	36,166	36,166	36,166	36,166	36,166	36,166	36,166	36,166	36,166	36,166	36,166	36,166	36,166	36,166	36,166	36,166	36,166	36,166	36,166	36,166	36,166	36,166	36,166	36,166	36,166	36,166	36,166
deferred rent																														130,216	130,216			130,216	130,216			130,216	130,216	130,216		130,216	130,216	130,216	130,216	130,216	110,284	117,501	117,501	111,250	111,250	111,250	111,250	111,250	97,880	87,234
accounts receivable, trade, net of allowance for doubtful accounts of 0 and 5,575 at june 30, 2018 and december 31, 2017, respectively																															2,166,415
product sales																															5,177,854
cost of product sales																															1,536,779									771,005
gross profit																															3,641,075									1,081,012
operating expenses
research and development																															324,612									504,239
sales and marketing																															641,168									733,913
general and administrative																															1,390,524									1,335,292
total operating expenses																															2,356,304									2,573,444
operating income																															1,284,771									-1,492,432
other income (expenses)
interest income																															32,537									1,919
interest expense																															-1,332
amortization of debt discount
income from equity-method investment in savsu																															-176,798
total other income (expenses)																															-145,593
net income before benefit from income taxes																															1,139,178
income taxes
net income after benefit from income taxes																															1,139,178
less: preferred stock dividends																															-93,258
net income attributable to common stockholders																															1,045,920
basic net income per common share																															0.07
diluted net income per common share																															0.05
basic shares used to compute earnings per share																															15,180,169
diluted shares used to compute earnings per share																															20,374,358
accounts receivable, trade, net of allowance for doubtful accounts of 5,575 at march 31, 2018 and december 31, 2017																																1,043,815
accounts receivable, trade, net of allowance for doubtful accounts of 5,575 and 0 at december 31, 2017 and 2016, respectively																																	1,021,315
promissory note payable to related party, net of discount of 155,996 at december 31, 2016																																					2,844,004
accrued interest, related party																																			33,274	181,190	97,857	39,524	8,333
total biolife solutions, inc. shareholders’ equity																																	10,092,586						6,822,439	7,442,610
23
accounts receivable, trade, net of allowance for doubtful accounts of 6,575 and 0 at september 30, 2017 and december 31, 2016, respectively																																		1,355,115
3
accounts receivable, trade, net of allowance for doubtful accounts of 8,913 and 0 at june 30, 2017 and december 31, 2016, respectively																																			1,173,036
accounts receivable, trade, net of allowance for doubtful accounts of 15,798 and 0 at march 31, 2017 and december 31, 2016																																				1,060,773
promissory note payable to related party, net of discount of 62,398 and 155,996 at march 31, 2017 and december 31, 2016																																				3,937,602
deferred rent, long term																																				590,716	685,450	713,751	740,888	766,044	784,458	809,275	832,976	848,041	874,825	874,825	753,842	795,145	840,730	891,986	918,307	942,955	798,084	838,829	714,391	697,878
short term investments																																									1,651,341	2,902,105	2,956,428	5,606,453	7,399,636	7,399,636	7,744,285	6,012,309
accounts receivable, trade, net of allowance for doubtful accounts of 0 at december 31, 2016 and 2015																																					1,193,646
internal use software																																						2,250,638	2,021,489	1,836,220	1,698,735	1,187,022	762,860	334,640
intangible asset																																						2,215,385	2,215,385	2,215,385	2,215,385	2,215,385	2,215,385	2,215,385	2,215,385	2,215,385
shareholders' equity
total biolife solutions, inc. shareholders' equity																																					3,166,140	6,161,527			8,508,471	9,151,891	10,021,514	10,836,437	11,803,977	11,803,977
total non-controlling interest equity																																						426,612	723,586	1,087,215	1,350,900	1,632,510	1,855,541	2,011,557	2,132,340	2,132,340
total shareholders' equity																																					3,166,140	6,588,139			9,859,371	10,784,401	11,877,055	12,847,994	13,936,317	13,936,317	12,667,207	13,398,416	14,077,149	-13,271,521		-12,662,694	-12,400,359	-12,486,023	-12,035,782	-11,740,688	-11,430,675	-11,180,486			-10,100,405	-9,548,912				-7,826,982
total liabilities and shareholders' equity																																					7,926,614	10,766,378			12,369,622	13,225,577	13,870,187	15,160,420	16,072,918	16,072,918	14,254,063	14,806,565	15,981,534	3,353,342	3,207,024	3,437,081	3,419,277	3,169,829	3,417,833	3,068,907	1,869,170	1,662,017			1,386,251	1,309,059				1,333,958
accounts receivable, trade, net of allowance for doubtful accounts of 0 at september 30, 2016 and december 31, 2015																																						1,311,006
note payable, related party, net of discount of 249,593 at september 30, 2016																																						1,750,407
accounts receivable, trade, net of allowance for doubtful accounts of 0 at june 30, 2016 and december 31, 2015																																							1,284,015
note payable, related party, net of discount of 343,191 at june 30, 2016																																							656,809
accounts receivable, trade, net of allowance for doubtful accounts of 0 at march 31, 2016 and december 31, 2015																																								1,190,260
long term liabilities
product revenue																																								1,852,017
other income
net income																																								-1,490,513
net income attributable to non-controlling interest																																								263,685
net income attributable to biolife solutions, inc.																																								-1,226,828
basic and diluted net income per common share attributable to biolife solutions, inc.																																								-0.1
basic and diluted weighted-average common shares used to calculate net income per common share																																								12,457,858
accounts receivable, trade, net of allowance for doubtful accounts of 0 at december 31, 2015 and 2014																																									929,289
accounts receivable, trade, net of allowance for doubtful accounts of 0 at september 30, 2015 and december 31, 2014																																										792,274
accounts receivable, trade, net of allowance for doubtful accounts of 0 at june 30, 2015 and december 31, 2014																																											809,387
accounts receivable, trade, net of allowance for doubtful accounts of 0 at march 31, 2015 and december 31, 2014																																												851,044
accounts receivable, trade, net of allowance for doubtful accounts of 0 at december 31, 2014 and 1,100 at december 31, 2013																																													901,623	901,623
deferred financing costs																																																		114,874	129,136	143,399	157,506	171,458	189,855	208,251	84,997	112,042	139,384	70,466	81,896	97,220
promissory notes payable, related parties																																																		10,603,127	10,603,127	10,603,127	10,603,127	10,603,127	10,603,127	10,603,127	10,303,127	10,128,127	9,903,127	9,653,127	9,383,127	9,033,127	8,738,127	8,488,127	8,138,127	7,888,127	7,588,127	6,963,127	6,463,127	4,463,127	3,963,127	3,463,127
accrued interest, related parties																																																		3,501,610	3,316,055	3,130,501	2,944,946	2,759,391	2,573,836	2,388,281	2,204,738	2,025,961	1,852,433	1,680,756	1,515,517	1,354,975	1,199,601	1,049,038	903,346	766,973	632,372	504,080	385,814	193,778
accounts receivable, trade, net of allowance for doubtful accounts of 1,100 at september 30, 2014 and december 31, 2013																																															775,076
deferred revenue																																															90,000							20,000	20,000	178,717	20,000	20,000	20,000	20,000	20,000	20,000	20,000	20,000	20,000	20,000	25,833	8,334	19,166	109,583		7,083
accumulated other comprehensive																																															-6,606
accounts receivable, trade, net of allowance for doubtful accounts of 1,100 at june 30, 2014 and december 31, 2013																																																566,540
accounts receivable, trade, net of allowance for doubtful accounts of 1,100 at march 31, 2014 and december 31, 2013																																																	1,325,564
accounts receivable, trade, net of allowance for doubtful accounts of 1,100 at december 31, 2013 and 2012																																																		1,009,316
deferred revenue, long term																																																						89,167	94,167	99,167	104,167	109,167	114,167	119,167	124,167	129,167	134,167	139,167	144,167	149,167	154,167	67,500	70,000
accounts receivable, trade, net of allowance for doubtful accounts of 1,100 at september 30, 2013 and december 31, 2012																																																			1,026,858
accounts receivable, trade, net of allowance for doubtful accounts of 1,100 at june 30, 2013 and december 31, 2012																																																				980,974
accounts receivable, trade, net of allowance for doubtful accounts of 1,100 at march 31, 2013 and december 31, 2012																																																					976,157
accounts receivable, trade, net of allowance for doubtful accounts of 1,100 at december 31, 2012 and 2011																																																						600,153
accounts receivable, trade, net of allowance for doubtful accounts of 1,100 at september 30, 2012 and december 31, 2011																																																							797,943
accounts receivable, trade, net of allowance for doubtful accounts of 1,100 at june 30, 2012 and december 31, 2011																																																								359,190
accounts receivable, trade, net of allowance for doubtful accounts of 1,100 at march 31, 2012 and december 31, 2011																																																									471,816
accounts receivable, trade, net of allowance for doubtful accounts of 1,100 at december 31, 2011 and 2010																																																										547,143
accounts receivable, trade, net of allowance for doubtful accounts of 1,100 at both september 30, 2011 and december 31, 2010
less: accumulated depreciation and amortization																																																											-423,104	-398,524			-330,225	-308,343	-285,260	-281,036	-254,224	-228,438	-199,788	-181,582	-174,532	-151,735
liabilities and stockholders’ equity
accrued expenses																																																											100,445	48,022			88,867	57,841	70,630	51,251	196,284	222,425	203,929	265,879	144,950	150,208
stockholders' equity
total stockholders' equity																																																											-10,821,499	-10,483,843			-9,218,113	-8,816,680	-8,322,150		-7,498,600	-6,962,293	-5,982,886	-4,384,400	-3,738,318	-3,089,522
total liabilities and stockholders' equity																																																											1,564,376	1,471,981			1,293,655	1,384,760	1,328,018		1,310,008	1,203,450	1,745,300	1,302,592	850,725	854,527
accounts receivable, trade, net of allowance for doubtful accounts
of 1,100 at june 30, 2011 and december 31, 2010, respectively																																																												395,324
authorized, 69,679,854 issued and outstanding at june 30, 2011 and december 31, 2010																																																												69,680
accounts receivable, trade, net of allowance for doubtful accounts of 1,100 at march 31, 2011 and december 31, 2010, respectively																																																													356,701
accounts receivable, trade, net of allowance for doubtful accounts of 1,100 and 550 at december 31, 2010 and 2009, respectively																																																														338,899
of 7,400 and 550 at september 30, 2010 and december 31, 2009, respectively																																																															317,058
authorized, 69,679,854 issued and outstanding
at september 30, 2010 and december 31, 2009																																																															69,680
of 39,900 and 550 at june 30, 2010 and december 31, 2009, respectively																																																																285,241
authorized, 69,679,854 issued and outstanding at june 30, 2010 and december 31, 2009																																																																69,680
of 20,600 and 550 at march 31, 2010 and december 31, 2009, respectively																																																																	358,772
authorized, 69,679,854 issued and outstanding at march 31, 2010 and december 31, 2009																																																																	69,680
accounts receivable, trade, net of allowance for doubtful accounts of 550 and 29,000 at december 31, 2009 and 2008, respectively																																																																		315,365
accounts receivable, trade, net of allowance for doubtful accounts of 5,000 and 29,000 at september 30, 2009 and december 31, 2008, respectively																																																																			369,329
accounts receivable, trade, net of allowance for doubtful accounts of 9,000 and 29,000 at june 30, 2009 and december 31, 2008, respectively																																																																				199,192
accounts receivable, trade, net of allowance for doubtful accounts of 12,000 and 29,000 at march 31, 2009 and december 31, 2008, respectively																																																																					244,963
other receivable																																																																					79,904
modular clean room																																																																					202,270
accounts receivable, trade, net of allowance for doubtful accounts of 5,000 at both september 30, 2008 and december 31, 2007																																																																						362,145
prepaid expenses																																																																						133,257	292,440	285,068
shares authorized, 69,639,854 and 69,606,520 shares issued and outstanding at september 30, 2008 and december 31, 2007, respectively																																																																						69,640
accounts receivable, trade, net of allowance for doubtful accounts of 3,000 and 5,000 at june 30, 2008 and december 31, 2007, respectively																																																																							228,931
other current assets																																																																							14,167	10,000
of 3,000 and 5,000 at march 31, 2008 and december 31, 2007, respectively																																																																								214,751
shares authorized, 69,639,854 and 69,606,520 shares issued and outstanding at march 31, 2008 and december 31, 2007																																																																								69,640

Cashflow Statements:

Quarterly

Annual

Unit: USD	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-06-30	2018-03-31	2017-09-30	2017-06-30	2016-09-30	2015-09-30	2015-06-30	2015-03-31	2014-03-31	2012-03-31	2011-12-31	2009-09-30	2009-06-30	2009-03-31

cash flows from operating activities
net loss	11,070,000	621,000	-15,838,000	-448,000	12,459,000	-1,703,000	-20,719,000	-10,221,000		-29,132,000	-10,199,000	-13,714,000				-7,066,000															-1,957,220	-1,638,502	-4,476,200	-3,594,379	-2,302,660	-1,152,265	-559,371	-296,877		-2,413,118	-1,850,495	-839,568
adjustments to reconcile net loss to net cash from operating activities
impairment of intangible assets									0
impairment of long-lived assets									0
gain on settlement of global cooling escrow
depreciation	261,000	636,000	674,000	682,000	937,000	1,407,000	1,452,000	1,364,000	1,468,000	1,922,000	2,003,000	1,721,000	1,719,000	1,799,000	1,604,000	1,653,000	1,628,000	1,140,000	1,118,000	777,000	581,000	481,000	560,000	413,000	373,000	209,000	98,000	93,073	161,200	77,823	259,895	176,251	276,346	255,548	168,727	83,646	62,506	26,455		66,879	40,159	9,573
amortization of intangible assets	325,000	699,000	708,000	702,000	767,000	910,000	910,000	914,000	915,000	1,355,000	1,452,000	1,459,000	1,461,000	2,511,000	2,862,000	2,863,000	2,862,000	2,525,000	1,882,000	933,000	933,000	706,000	706,000	688,000	465,000	104,000
amortization of loan costs									0	0	0	13,000
stock-based compensation	7,077,000	5,904,000	5,859,000	4,153,000	10,692,000	5,329,000	8,719,000	6,183,000	8,333,000	9,117,000	6,857,000	7,363,000	7,663,000	6,299,000	5,973,000	5,399,000	5,065,000	4,867,000	2,519,000	1,505,000	2,163,000	1,560,000	1,145,000	1,113,000
non-cash lease expense	-118,000	1,323,000	358,000	312,000	159,000	404,000	-56,000	-83,000	-90,000	466,000	-390,000	418,000	2,461,000	-283,000	784,000	524,000	258,000	748,000
deferred income tax expense	0	14,000	45,000	6,000		-93,000	0	5,000		23,000	0	13,000
change in fair value of contingent consideration									-415,000	-1,580,000	-918,000	720,000	-1,406,000	2,347,000	-2,360,000	-3,335,000	1,789,000	-140,000	1,717,000	-491,000	3,103,000	-2,000	-1,463,000	-63,000
change in fair value of equity investment and other
accretion of investments									-213,000			-390,000
loss on disposal of assets held for rent	0	167,000	156,000	187,000	109,000	123,000	137,000	198,000	151,000	107,000	118,000	218,000	404,000	633,000	-168,000	-96,000	276,000	231,000	37,000	65,000
loss on disposal of property and equipment					216,000	4,000	-52,000	-14,000	406,000	12,000	147,000	68,000	691,000	19,000	17,000	18,000									13,000								1,213					63	-283	3,734	2,123
ipr&d expense	0	0
net gain on disposal of subsidiaries
change in operating assets and liabilities
accounts receivable, trade	1,938,000	-782,000	-893,000	1,000	-1,233,000	208,000	-1,939,000	65,000	5,914,000	2,346,000	3,479,000	3,612,000	-1,315,000	-1,310,000	-7,045,000	-1,083,000	-2,992,000	1,354,000	-5,831,000	-2,663,000	-966,000	-1,744,000	3,853,000	-2,929,000	-372,000	-632,000	118,000	-345,973	-1,145,100	-22,500	-159,851	20,610	-381,717	109,349	92,236	50,579	-316,248	75,327	-88,466	-90,137	80,000	34,229
inventories	-2,331,000	-197,000	-187,000	1,447,000	-1,343,000	317,000	1,765,000	42,000	-102,000	-4,177,000	2,152,000	-6,425,000	-1,156,000	-413,000	-3,135,000	-1,855,000	1,351,000	-2,520,000	1,348,000	-65,000	-564,000	-147,000	-61,000	143,000	-1,730,000	-1,341,000	-551,000	-597,819	-275,135	10,080	-103,274	-11,286	-69,124	-818,159	-356,033	-277,563	123,819	-258,011	-30,830	387,639	246,060	172,280
prepaid expenses and other current assets																	1,033,000	-601,000	2,318,000	52,000	-43,000	-188,000	-61,000	317,000	-272,000	-32,000	6,000	-55,394	-103,108	11,598	-101,479	-135,905	-29,692	-86,405	47,762	72,156	88,961	22,145			-43,503	-122,664
accounts payable	-952,000	-679,000	373,000	-828,000	1,165,000	-373,000	1,190,000	-1,956,000	-5,045,000	1,301,000	-4,838,000	157,000	4,029,000	-213,000	-171,000	-3,231,000	650,000	4,158,000	-3,394,000	604,000	433,000	-667,000	-498,000	561,000	377,000	-36,000	553,000	-353,875	168,005	-68,743	-227,732	-124,239	361,900	253,647	-99,771	221,046	-159,087	130,898	92,661	-447,308	-258,856	-72,982
accrued expenses and other current liabilities	680,000	1,564,000	864,000	-4,252,000	6,581,000	262,000	2,409,000	-2,767,000	3,694,000	-1,802,000	-261,000	371,000	1,343,000	1,477,000	41,000	-1,074,000	-1,406,000	1,352,000	-5,571,000	1,689,000				304,000
sales taxes payable	-1,385,000	105,000	-298,000	-327,000	-84,000	-501,000	-408,000	20,000	-19,000	412,000	408,000	510,000
warranty liability					-50,000	4,000	-424,000	-58,000	-357,000	-221,000	-459,000	583,000	-55,000	-355,000
other				16,000		-1,000	112,000	-377,000		181,000	-3,000	-50,000	-136,000	102,000	217,000	-17,000	-151,000	329,000	174,000	1,000	181,000			-402,000
net cash from operating activities	4,916,000	6,104,000	7,368,000	1,727,000	1,645,000	4,802,000	6,459,000	-4,475,000	2,311,000	-4,379,000	-7,718,000	-2,712,000	7,857,000	1,496,000	-9,917,000	-7,924,000	-774,000	2,083,000	-7,722,000	1,820,000	2,257,000	-502,000	4,203,000	687,000	2,216,000	1,079,000	1,146,000	585,480	953,315	391,589	-197,889	-272,268	-3,658,871	-3,703,591	-2,534,961	-1,307,852	-894,126	-74,823	-192,795	-2,155,160	-1,542,332	-811,807
capital expenditures	-4,258,000	-2,942,000	-2,205,000	377,000	-752,000	-1,319,000	-719,000	-330,000	-4,686,000	1,738,000	-126,000	-2,948,000	-5,631,000	-887,000	-1,946,000	-1,443,000	-1,674,000	-2,412,000	-2,687,000	-1,720,000	-1,591,000	-119,000	-82,000	-140,000	-210,000	-263,000	-110,000	-156,033	-41,620	-40,834	-39,116	-25,858	-130,118	-103,856	-72,009	-41,128	-18,777	-47,217	0	-372,750	-369,989	-258,721
free cash flows	658,000	3,162,000	5,163,000	2,104,000	893,000	3,483,000	5,740,000	-4,805,000	-2,375,000	-2,641,000	-7,844,000	-5,660,000	2,226,000	609,000	-11,863,000	-9,367,000	-2,448,000	-329,000	-10,409,000	100,000	666,000	-621,000	4,121,000	547,000	2,006,000	816,000	1,036,000	429,447	911,695	350,755	-237,005	-298,126	-3,788,989	-3,807,447	-2,606,970	-1,348,980	-912,903	-122,040	-192,795	-2,527,910	-1,912,321	-1,070,528
cash flows from investing activities
purchases of property and equipment	-4,258,000	-3,302,000	-1,743,000	-175,000	-762,000	-1,114,000	-995,000	-356,000	-981,000	-1,496,000	-609,000	-3,295,000	-4,448,000	-2,446,000	-2,035,000	-1,456,000	-1,566,000	-2,412,000	-2,687,000	-1,720,000
purchases of assets held for rent	-101,000	-373,000	-162,000	-250,000	-40,000	-434,000	-1,130,000	-464,000	-1,403,000	-901,000	-1,551,000	-1,001,000	-1,267,000	-1,495,000	40,000	-814,000
proceeds from sale of available-for-sale securities	3,238,000	1,836,000	1,182,000	573,000	909,000	819,000	817,000	973,000	498,000	1,119,000	1,328,000	524,000
maturities of available-for-sale securities	15,412,000	10,962,000	5,390,000	3,000,000	2,800,000	4,350,000	5,250,000	6,000,000	10,250,000	9,900,000	17,650,000	14,900,000
investment in available-for-sale securities													-17,349,000	-12,692,000
purchases of intangible assets
investment in ipr&d	0	0
investment in convertible promissory note	0
proceeds from sale of divested entities
payments on divestiture of global cooling					0	0
net cash from investing activities	1,137,000	-5,967,000	-39,533,000	-27,176,000	73,637,000	-1,681,000	-13,435,000	-221,000	3,957,000	1,662,000	9,292,000	2,926,000	-14,894,000	-15,883,000	-25,070,000	-2,270,000	-2,542,000	-2,007,000	-4,216,000	-4,427,000	-22,057,000	-975,000	-456,000	-1,227,000	-12,997,000	-12,705,000	-156,000	-160,932	-1,061,479	-40,834	-91,443	-78,185	662,429	3,416,387			-18,777	-46,517
cash flows from financing activities
payments on term loan
payments on equipment loans					-926,000	-214,000	-227,000	-241,000	185,000	-127,000	-129,000	-127,000	-128,000	-123,000	-122,000	-125,000
issuance of common stock
proceeds from exercise of common stock options									137,000	64,000	181,000	125,000	16,000	6,000	44,000	257,000	401,000	409,000	365,000	243,000	443,000	245,000	293,000	490,000										99,986	79,969	24,934
proceeds from financed insurance premium					0				0
payments on financed insurance premium	0	-67,000	-406,000	-502,000	-667,000	-483,000	-520,000	-727,000	-712,000	-1,761,000	677,000	-569,000	-561,000	-356,000	-153,000	-305,000	-335,000	-511,000
net cash from financing activities	-2,496,000	-2,558,000	-2,878,000	-2,992,000	-4,086,000	-1,041,000	-704,000	-952,000	9,841,000	608,000	704,000	-562,000	-625,000	17,411,000	-289,000	-181,000	-2,105,000	-1,058,000	-831,000	1,216,000	1,272,000	80,582,000	19,732,000	492,000	1,329,000	586,000	177,000	-2,147,904	7,611,450	18,440	1,714,047	1,259,260	2,191,767	99,986	79,969	24,934	13,596,230			2,525,000	1,900,000	1,400,000
net increase in cash and cash equivalents																							23,479,000	-48,000	-9,452,000	-11,040,000	1,167,000	-1,723,356	7,503,286	369,195	1,424,715	908,807		-187,218	1,357,647	433,082	12,683,327	53,660	-3,253	-2,910	-12,321	329,472
cash and cash equivalents – beginning of period	0	0
effects of currency translation on cash and cash equivalents
cash and cash equivalents – end of period	3,557,000	-2,421,000
non-cash investing and financing activities
assets acquired under operating leases					531,000	4,993,000			1,760,000
assets acquired under finance leases
purchase of property and equipment not yet paid		360,000	-462,000	552,000	10,000	-205,000	276,000	26,000	-3,705,000	3,234,000	483,000	347,000	-1,183,000	1,559,000	89,000	13,000	-108,000								146,000	4,000		4,899	19,859
unrealized loss on available-for-sale securities
unrealized gain on currency translation
non-cash acquisition of panthera	0	0
cashless issuance of scisafe earnout shares									0	0				1,000
returned shares from settlement of global cooling escrow									0
cash interest paid	118,000	164,000	215,000	265,000	372,000	407,000	384,000	445,000	533,000	459,000	438,000	497,000	356,000	109,000	30,000	91,000
change in fair value of investments, inclusive of interest
accretion of available-for-sale investments		-230,000	-200,000	-105,000		-89,000	-136,000	-182,000
gain on disposal of property and equipment
loss on disposal of global cooling						0
change in operating assets and liabilities, net of effects of acquisitions
prepaid expenses and other assets		-3,000,000	242,000	181,000		-1,406,000	528,000	2,392,000		138,000	-1,844,000	661,000		136,000	-1,467,000	-25,000																								-137,663
purchases of available-for-sale securities		-13,090,000	-33,979,000	-30,324,000		-5,302,000	-4,338,000	-6,374,000		-6,960,000	-7,526,000	-8,202,000
proceeds from exercises of common stock options		0				46,000
payments on term loans		-2,500,000	-2,500,000	-2,500,000
net decrease in cash and cash equivalents		-2,421,000																															-804,675
unrealized gains on currency translation
unrealized gains on available-for-sale securities				-9,000
change in fair value of equity investments						0
unrealized losses on available-for-sale securities
net decrease in cash, cash equivalents, and restricted cash				-28,441,000				-5,648,000		-2,109,000	2,278,000	-348,000	-7,662,000	3,024,000	-35,276,000	-10,375,000				-1,391,000
cash, cash equivalents, and restricted cash – beginning of period				95,386,000		0	0	35,438,000	0	0	0	19,473,000	0	0	0	69,870,000	0	0
effects of currency translation on cash, cash equivalents, and restricted cash						36,000	0	-65,000	63,000	-56,000	17,000	11,000	68,000	14,000	-168,000	-22,000	140,000	-166,000
cash, cash equivalents, and restricted cash – end of period				66,945,000		2,116,000	-7,680,000	29,725,000	16,172,000	-2,165,000	2,295,000	19,136,000	-7,594,000	3,038,000	-35,444,000	59,473,000	-5,281,000	-1,148,000
deferred income tax benefit													-301,000	-599,000			-2,587,000	-4,988,000
change in fair value of investments																					-209,000
proceeds from sale of scisafe and cbs
proceeds from term loan
fees paid related to issuance of common stock													-1,000			-50,000	0
settlement of global cooling escrow										0
assets acquired under financing leases
net increase in cash, cash equivalents, and restricted cash																	-5,421,000	-982,000
unrealized gains and losses on currency translation							10,000	-6,000
unrealized gains and losses on available-for-sale securities							0	18,000		-7,000	2,000	-39,000
net income													-50,228,000	-9,957,000			-14,472,000	79,000	7,876,000	-1,118,000	-2,128,000	-1,133,000	-16,380,000	22,308,000	10,581,000	1,265,000	427,000	892,571	1,142,660	3,482									-411,170
adjustments to reconcile net income to net cash from operating activities
change in fair value of warrant liability																	0	0	0	121,000	866,000	1,005,000	16,442,000	-21,914,000
gain on acquisition of sexton biotechnologies, inc.																	0
forgiveness of loans payable
cash acquired in acquisition of global cooling, inc. and sexton biotechnologies, inc.																	0
proceeds from sale of equipment																	-17,000	21,000	-2,000	3,000	32,000
proceeds from equipment loans																	-90,000	358,000	230,000	1,052,000
proceeds from line of credit																	856,000	14,650,000
payments on line of credit																	-2,879,000	-15,919,000
cashless exercise of warrants reclassified from warrant liability to common stock																	0	0
stock issued as consideration to acquire global cooling, inc. and sexton biotechnologies, inc.																	0
unrealized (gain) loss on available-for-sale securities
proceeds from term loans
amortization of investments
fees incurred for registration filings
equipment acquired under operating leases											0	880,000	0	0	0	243,000	-96,000	0	5,739,000	1,232,000
stock issued for services																					30,000										71,250	35,625
sales taxes payable
payments related to the acquisition of scisafe, net of cash acquired
investment in ivexsol preferred stock
investment in panthera cryosolutions
deposits on property and equipment																				-672,000
deposits on assets held for rent
proceeds from sale of marketable securities
maturities of marketable securities
proceeds from paycheck protection program ("ppp") loan
payoff of ppp loan																					0	0
payments of contingent consideration																					0	0
proceeds from sale of common stock, net of 6.2 million of costs in 2020
proceeds from exercise of warrants																					0	16,000	15,000	9,000
equipment acquired under finance leases																	0	0	0	440,000
unrealized gains and losses on available-for-sale-securities
reclassification of warrant liabilities to equity upon exercise
stock issued as consideration to acquire scisafe
stock issued as bonus consideration																					0	0
intangible asset impairment charges														0
cash acquired in acquisition of global cooling, inc.
stock issued as consideration to acquire global cooling, inc.
deferred income tax benefits																-599,000
reclassification of property and equipment, net to assets held for rent																				27,000
loss from equity method investment in savsu																									739,000
gain on acquisition of savsu																									-10,108,000
cash acquired in acquisition of savsu
acquisition of astero bio, net of cash acquired
payments related to the acquisition of cbs
investment in sexton
investment in ivexsol convertible debt
stock issued as consideration to acquire savsu																									19,932,000
stock issued as consideration to acquire assets of cbs
purchases of assets held for lease																		-1,132,000	-2,242,000	-2,038,000
financing costs paid in a prior period
stock issued as a prepayment of services
purchase of equipment with debt																						137,000						396	17,604	17,604	39,243	39,243
deferred financing costs not yet paid
non cash lease expense																				410,000	282,000	155,000	152,000	148,000
cash, cash equivalents, and restricted cash – beginning of year																				90,456,000
cash, cash equivalents, and restricted cash – end of year																				89,065,000
cashless exercise of warrants reclassed from warrant liability to common stock																				2,901,000	0	0
payments related to the acquisition of cbs
purchase of property and equipment																					-1,591,000	-119,000	-105,000	-146,000	-356,000	-267,000	-156,000	-160,932	-61,479	-40,834	-91,443	-78,185	-130,118	-103,856	-72,009	-41,128	-18,777	-47,217		-372,750	-369,989	-258,721
purchase of assets held for lease
deposits on assets held for lease
proceeds from ppp loan																					0	0
proceeds from sale of common stock, net of 6.2 million of costs																					-130,000
payment of costs related to stock issuance
other payables
accrued compensation and other current liabilities																						512,000			558,000	-20,000	-302,000	292,347	5,813	-102,643	138,885	56,442	-107,586	-175,482	-267,229	-353,077	-411,650
payments related to the scisafe acquisition
cash acquired on acquisition of savsu																									1,251,000
payments related to the astero bio acquisition, net of cash acquired																									-12,439,000	-12,438,000
investment in ivexsol																									-1,000,000
purchase of assets held for rent																						-359,000	-351,000	-1,081,000	-453,000
payments of costs related to stock issuance
net increase in cash, cash equivalents and restricted cash
cash, cash equivalents and restricted cash - beginning of period
cash, cash equivalents and restricted cash - end of period
reclassification of warrant liability to equity upon exercise																						53,000	36,000	21,000
purchase of property & equipment not yet paid																						0	23,000	6,000			46,000
stock issued as prepayment of services
proceeds from sale of common stock, net of fees
cash and cash equivalents - beginning of period																							0	6,448,000	30,657,000	30,657,000	30,657,000		6,663,318	6,663,318	1,405,826	1,405,826	2,173,258	2,538,758	2,538,758	2,538,758	156,273	16,864		98,724	98,724	98,724
cash and cash equivalents - end of period																							23,479,000	6,400,000	21,205,000	19,617,000	31,824,000		14,166,604	7,032,513	2,830,541	2,314,633	1,368,583	2,351,540	3,896,405	2,971,840	12,839,600	70,524		95,814	86,403	428,196
gain from equity method investment in savsu
stock issued as 2019 bonus payout																								314,000
other liabilities																									-98,000	-53,000
investment in savsu																												0
stock issue from private equity transaction
payments for redemption of preferred stock																												-3,187,000	-1,063,000
payments of preferred stock dividends																												-130,242	-212,500	-106,250
cash and cash equivalents – beginning of year
cash and cash equivalents – end of year
stock issued for services in prior period included in liabilities at prior year-end
receivables converted to equity investment in savsu																												-103	150,103
legal fees for private equity transaction not yet paid																												1,500
stock-based compensation expense																									1,907,000	1,252,000	606,000	388,055	747,805	373,425	957,711	643,768	583,847	336,630	158,371	33,509	51,619	46,688
amortization of deferred rent related to lease incentives																												-31,752	-63,499	-31,749	-95,249	-63,499	-95,248	-95,250	-63,500	-31,750
amortization of operating lease liability																									-132,000	-87,000	-43,000
interest expense – finance type lease																									2,000	2,000	2,000
decrease in
other assets																									-87,000
increase in
proceeds from private equity transaction																												6
payment of costs related to stock issuances																									-44,000
payments on equipment loan																									-12,000	-8,000	-4,000	-2,733	-5,441	-1,635	-10,628	-8,176
payments on finance lease obligations																									-9,000
proceeds from exercise of common stock options and warrants																									1,394,000	601,000	185,000	1,175,753	8,898,932	129,596	784,273	314,024	278,503
series a preferred stock dividends accrued not yet paid																													93,258	106,250
stock issued for services provided in prior period included in liabilities at year-end																													35,625	35,625	35,624	35,624
financing costs not yet paid																									53,000
loss from equity-method investment in savsu																										448,000	232,000	308,757	320,554	143,756	707,208	489,473
deferred rent																												-4,510	-5,880	-2,940	-63,836	-62,419	24,541	29,700	21,651	4,966	-5,227
investment in equity investment savsu																													-1,000,000
payments on capital lease obligations																										-7,000			-6,541		-7,631	-4,360
payments on capital lease obligation/finance lease																											-4,000
cash received in advance of issuance of stock on warrant exercises
write off of deferred financing costs
amortization of debt discount																															155,996	155,996	124,797
accrued interest																															152,143
proceeds from note payable to related party
payments on capital lease obligation																														-3,271
payments related to stock issuance
deferred costs paid related to potential stock issuance
cash and cash equivalents - beginning of year
cash and cash equivalents - end of year
preferred stock issued to convert related party note payable and accrued interest
capital lease obligations incurred for purchase of equipment
write-off of deferred financing costs																															67,664		86,736
proceeds from related party debt																															1,000,000	1,000,000	2,000,000
payments of costs related to stock issuances
deferred costs related to potential stock issuance																															-42,664	-42,228	-86,736
preferred stock issued on conversion of related party note payable and accrued interest																															4,250,000	4,250,000
capital lease obligations incurred for purchases of equipment																															52,327	52,327
preferred stock issuance costs not yet paid																																8,038
accrued interest, related party																																185,417
proceeds from note payable
deferred costs related to security issuance
non-cash financing activity
deferred costs related to security issuance not yet paid as of quarter end
loss on deconsolidation of biologistex
accretion and amortization on available for sale investments																																	1,792	81,210	65,485	40,901
sales/maturities of available-for-sale investments
costs associated with internal use software development																																	-857,453	-895,062	-497,480
payments related to preferred stock issuance																															-9,303
stock issued for services in prior period included in liabilities at year-end
debt discount related to warrants																																	374,390
deferred costs related to potential stock issuances not yet paid
sales of available-for-sale investments																																	1,650,000	5,825,000	4,725,000	2,100,000
costs incurred for capitalized internal use software not paid as of quarter end																																	109,500	291,960	265,380	334,640
preferred stock dividends accrued																															106,250
amortization debt discount
income from equity-method investment in savsu
option exercises for which cash not yet received as of quarter end
purchase of available-for-sale investments
costs incurred for capitalized internal use software not paid as of year-end
proceeds from issuance of common stock on exercise of common stock options not received as of year-end
deferred costs related to stock issuance not yet paid
accrued interest, related parties																																	39,524				177,308	178,777	173,528	353,412	225,120	106,853
purchases of available-for-sale investments																																		-1,409,695	-342,872	-342,872
net provided by investing activities
non-cash investing activity
amortization of deferred financing costs																																					13,022	27,045	27,342
lease incentives, net of amortization of deferred rent related to lease incentives
cash received from sale of property and equipment																																						700
proceeds from sale of common stock, net of expenses																																					13,596,230
acquisition of intangible asset from non-controlling interest
conversion of notes payable and related party accrued interest to equity, net of unamortized deferred finance costs																																					14,180,193
deferred revenue																																						-5,000	-5,000	81,667	-22,499	-9,167
proceeds from the sale of property and equipment
non-cash investing activities
non-cash financing activities
net from investing activities																																			3,812,639	1,716,000
lease incentives received from landlord, net of amortization of deferred rent related to lease incentives																																					-39,778
stock to be issued for services																																					80,000
purchase of available-for-sale investments, net of sales
proceeds from notes payable																																						175,000
deferred financing costs from issuance of warrants																																							0
amortization of deferred rent related to lease incentives, net of amount received from landlord
lease incentive received from landlord, net of amortization
prepaid expenses and other current assets and long-term deposits
accrued compensation and other incomes and other current liabilities
cash flows from financing activity
net cash from financing activity																																						175,000	225,000
accrued compensation and other expenses and other current liabilities																																						-22,333
depreciation and amortization
share-based compensation expense																																								85,630	59,315	27,794
accrued expenses and compensation
cash flows from investing activity
purchase of property and equipment, net of proceeds from disposals
net cash from investing activity																																								-372,750	-369,989	-258,721
proceeds from promissory notes payable, related parties																																								2,525,000	1,900,000	1,400,000
proceeds from exercise of options
other receivable																																										-79,904
accrued compensation and other incomes
accrued expenses																																								-45,896	-19,756	-38,251
non-cash items:
transfer of accrued interest to promissory notes payable
decrease in restricted cash
principal payments on note payable
collection of stock subscriptions receivable
stock issued in consideration for financing fees related to promissory notes payable
transfer of accrued interest, related parties, to promissory notes payable, related parties
stock issued in consideration for financing fees related to promissory notes payable, related parties

BioLife Solutions, Inc(NASDAQ:BLFS)

BioLife Solutions, Inc
(NASDAQ:BLFS)